Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2607494 | 0.90 | KMT2A (0.64) | KMT2AMEN1LMNAKDM4EMAPT | |
| SCHEMBL10175827 | 0.84 | KMT2A (0.70) | KMT2AMEN1LMNAKDM4EALDH1A1 | |
| SCHEMBL2607470 | 0.83 | KDM4E (0.69) | KMT2AMEN1LMNAKDM4EALDH1A1 | |
| SCHEMBL2607496 | 0.81 | KMT2A (0.66) | KMT2AMEN1LMNAKDM4EALDH1A1 | |
| SCHEMBL2607501 | 0.81 | GSK3B (0.69) | KMT2AMEN1LMNAKDM4EALDH1A1 | |
| SCHEMBL2607478 | 0.81 | KMT2A (0.68) | KMT2AMEN1LMNAKDM4EALDH1A1 | |
| SCHEMBL13182350 | 0.81 | KMT2A (0.65) | KMT2AMEN1LMNAKDM4EALDH1A1 | |
| SCHEMBL2610181 | 0.81 | MEN1 (0.68) | KMT2AMEN1LMNAKDM4EALDH1A1 | |
| SCHEMBL13182395 | 0.80 | MEN1 (0.64) | KMT2AMEN1LMNAKDM4EALDH1A1 | |
| SCHEMBL2607457 | 0.80 | KDM4E (0.73) | KMT2AMEN1LMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | University of Georgia Foundation, Inc. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2010108187-A2 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | BRANDEIS UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | IMPDH1, IMPDH2, IMPA1 | KMT2A 3016/4885MEN1 3561/4885LMNA 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.